NZ598702A - A micro-rna family that modulates fibrosis and uses thereof - Google Patents
A micro-rna family that modulates fibrosis and uses thereofInfo
- Publication number
- NZ598702A NZ598702A NZ598702A NZ59870208A NZ598702A NZ 598702 A NZ598702 A NZ 598702A NZ 598702 A NZ598702 A NZ 598702A NZ 59870208 A NZ59870208 A NZ 59870208A NZ 598702 A NZ598702 A NZ 598702A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mir
- sequence
- antisense oligonucleotide
- micro
- medicament
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 108091070501 miRNA Proteins 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 4
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 4
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 4
- 102000008186 Collagen Human genes 0.000 abstract 2
- 108010035532 Collagen Proteins 0.000 abstract 2
- 229920001436 collagen Polymers 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 108091088477 miR-29a stem-loop Proteins 0.000 abstract 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 abstract 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 abstract 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 abstract 2
- 108091007432 miR-29b Proteins 0.000 abstract 2
- 108091047189 miR-29c stem-loop Proteins 0.000 abstract 2
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 abstract 2
- 206010040925 Skin striae Diseases 0.000 abstract 1
- 208000031439 Striae Distensae Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
598702 Disclosed is the use of an antisense oligonucleotide for preparation of a medicament for treating pathologies or deficiencies that are characterized by a loss, lack, or underproduction of collagen, wherein the antisense oligonucleotide comprises a sequence that is at least partially complementary to a miR-29a (uagcaccaucugaaaucggu), miR-29b (uagcaccauuugaaaucagu), or miR-29c (uagcaccauuugaaaucggu) sequence. Further disclosed is the use of an antisense oligonucleotide for preparation of a medicament for increasing collagen deposition in a tissue for treatment of natural aging and stretch marks. Further disclosed is a composition formulated for topical administration comprising a pharmaceutically acceptable carrier and an antisense oligonucleotide comprising a sequence that is at least partially complementary to a miR-29a, miR-29b, and/or miR-29c sequence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ61479108A NZ614791A (en) | 2007-07-31 | 2008-07-31 | A micro-rna family that modulates fibrosis and uses thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95291707P | 2007-07-31 | 2007-07-31 | |
| US98030307P | 2007-10-16 | 2007-10-16 | |
| US4701408P | 2008-04-22 | 2008-04-22 | |
| NZ583024A NZ583024A (en) | 2007-07-31 | 2008-07-31 | An agonist of miR-29a, miR-29b or miR-29c that prevents tissue fibrosis and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598702A true NZ598702A (en) | 2014-01-31 |
Family
ID=50619560
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ61479108A NZ614791A (en) | 2007-07-31 | 2008-07-31 | A micro-rna family that modulates fibrosis and uses thereof |
| NZ598702A NZ598702A (en) | 2007-07-31 | 2008-07-31 | A micro-rna family that modulates fibrosis and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ61479108A NZ614791A (en) | 2007-07-31 | 2008-07-31 | A micro-rna family that modulates fibrosis and uses thereof |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN105030808B (en) |
| NZ (2) | NZ614791A (en) |
| PL (1) | PL2182969T3 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105420405B (en) * | 2015-12-30 | 2018-12-07 | 山东农业大学 | The cow's serum microRNA molecule of milk cow Fatty Liver Disease and cow in perinatal period related metabolic diseases label |
| WO2017219168A1 (en) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | Lentiviral vector for knocking down mirna-29a and mir-152 expressions, and application thereof |
| US20200376019A1 (en) * | 2017-11-30 | 2020-12-03 | MiRagen Therapeutics, Inc. | miR29 MIMICS FOR THE TREATMENT OF OCULAR FIBROSIS |
| CN108690846A (en) * | 2018-04-17 | 2018-10-23 | 上海大学 | Inhibit the application of MiR-29b gene expressions |
| CN109762883B (en) * | 2019-01-31 | 2020-01-21 | 温州医科大学 | Application of plasma/serum exosome hsa-miRNA-29-3p as glaucoma diagnosis marker |
| CN110283901A (en) * | 2019-07-25 | 2019-09-27 | 青岛大学 | MiRNA probe compositions, Primer composition and diagnosis of coronary heart disease kit for diagnosis of coronary heart disease |
| CN111249466B (en) * | 2020-03-14 | 2022-04-15 | 浙江大学医学院附属第一医院 | Application of Tanshinone IIA combined with miR-29b inhibitor in the preparation of drugs for the treatment of tendon adhesions |
| CN111647656A (en) * | 2020-05-15 | 2020-09-11 | 华中科技大学同济医学院附属同济医院 | Application of mir-29a gene in detection of liver cancer and liver fibrosis and construction method of conditional knock-in mouse of gene |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101485495B1 (en) * | 2006-08-01 | 2015-01-22 | 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | Identification of microRNAs that activate beta-myosin heavy chain expression |
-
2008
- 2008-07-31 PL PL08797006T patent/PL2182969T3/en unknown
- 2008-07-31 NZ NZ61479108A patent/NZ614791A/en not_active IP Right Cessation
- 2008-07-31 NZ NZ598702A patent/NZ598702A/en not_active IP Right Cessation
- 2008-07-31 CN CN201510363301.5A patent/CN105030808B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ614791A (en) | 2015-03-27 |
| CN105030808B (en) | 2018-12-14 |
| CN105030808A (en) | 2015-11-11 |
| PL2182969T3 (en) | 2017-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598702A (en) | A micro-rna family that modulates fibrosis and uses thereof | |
| EP4327867A3 (en) | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient | |
| EP4327888A3 (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| EP3210633A3 (en) | Compositions and their uses directed to huntingtin | |
| MX2010014234A (en) | Pyrazole compounds 436. | |
| NZ624783A (en) | Modulation of huntingtin expression | |
| MY147994A (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
| TW200635924A (en) | Chemical compounds | |
| SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
| UA105644C2 (en) | Methods of treating pulmonary disorders with liposomal amikacin formulations | |
| MX2011012122A (en) | Thiophene derivatives. | |
| WO2007143607A3 (en) | Method of treating atrophic vaginitis | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| WO2008045559A3 (en) | Methods of treating oral mucositis | |
| WO2007131232A3 (en) | Compositions and their uses directed to ptpr alpha | |
| TW200942529A (en) | Pyrrolidinyl derivatives and uses thereof | |
| TNSN08506A1 (en) | Substituted carboxamides | |
| MXPA05014184A (en) | Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas. | |
| UA102111C2 (en) | Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof | |
| WO2011028799A3 (en) | Ganglioside transmucosal formulations | |
| WO2007036771A3 (en) | Pantoprazole free acid form iii | |
| ATE462430T1 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING INCONTINENCE | |
| BRPI0602179A (en) | pharmaceutical composition comprising cyclobenzaprine and aceclofenac in combination | |
| WO2008012361A3 (en) | Dimethano-[1,3] dioxocino [6,5-d] pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain | |
| MX2008011017A (en) | Sigma receptor compounds. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 JUL 2015 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS Effective date: 20140507 |
|
| ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 1018264, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, 201 WEST 7TH STREET, AUSTIN, TX 78701, US Effective date: 20140808 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2016 BY CPA GLOBAL Effective date: 20150620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2017 BY CPA GLOBAL Effective date: 20160617 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2018 BY CPA GLOBAL Effective date: 20170615 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2019 BY CPA GLOBAL Effective date: 20180614 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2020 BY CPA GLOBAL Effective date: 20190620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2021 BY CPA GLOBAL Effective date: 20200723 |
|
| LAPS | Patent lapsed |